Cardio Diagnostics, Inc.

Real-time population cardiovascular risk intelligence platform

A population cardiovascular risk intelligence platform that integrates HIPAA-compliant anonymized clinical, industry, claims, and geographic data to offer comprehensive views of heart attack risk and coronary heart disease across populations. It enables organizations to quantify risk in real-time, project future costs, tailor benefits offerings, track population risk over time, and benchmark against regional and industry data. Serves employers, consultants, and healthcare systems.

BioPharma research platform for cardiovascular solution development

A biopharma research platform that leverages AI and epigenetics to enable and accelerate the discovery, development, and validation of novel biopharmaceuticals for cardiovascular diseases. Core capabilities include identifying novel epigenetic and genetic biomarkers, optimizing clinical trials through patient stratification, and developing custom post-market surveillance or companion diagnostic tests that are non-invasive and scalable.

Coronary heart disease detection and management blood test

A clinical blood test available by prescription that aids in the diagnosis of coronary heart disease and identifies specific molecular drivers for each patient. It evaluates six epigenetic and ten genetic biomarkers using AI to detect CHD signals with high sensitivity. The test can detect both obstructive and non-obstructive disease, is non-invasive and radiation-free, and provides actionable insights on biomarker impact and associated pathways to personalize care.

Three-year coronary heart disease event risk assessment blood test

A clinical blood test available by prescription that assesses the three-year risk of a coronary heart disease event, including heart attack and sudden death. It evaluates three epigenetic and five genetic biomarkers using AI to predict risk with high sensitivity. The test is 2x more sensitive than conventional risk calculators, non-invasive, requires no fasting, and DNA methylation biomarkers can change in response to intervention.